Short-course radiation with immunotherapy before surgery for retroperitoneal sarcoma
Part of Cancer, Injuries & trauma clinical trials.
This trial tests a new approach for people with a rare type of cancer called retroperitoneal sarcoma, which grows in the back of the belly. It combines a short course of radiation and an immunotherapy drug before surgery, aiming to shrink the tumor and improve the chances of successful removal.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of soft tissue sarcoma in your belly or pelvis that doctors think is hard to remove completely with surgery alone.
- You are 18 years or older.
- You are generally healthy enough to undergo surgery and radiation, with no major heart, liver, or kidney problems.
- Your tumor can be safely covered by a single radiation field, even if there are multiple spots.
- You have not had radiation to the same area before, and you do not have cancer that has spread to distant organs.
- You agree to use effective birth control during treatment and for 6 months after if you or your partner could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving a shorter, lower-dose radiation treatment before surgery for a retroperitoneal (deep belly/back space) soft-tissue sarcoma. The goal is to shrink or control the tumor and make surgery more effective and safe.
This trial tests a combination of radiation therapy and two drugs (anlotinib and penpulimab) given before surgery for soft tissue sarcoma. The goal is to see if this approach can shrink tumors and improve outcomes.
This study tests whether a short course of radiation before surgery can treat retroperitoneal sarcoma (a rare cancer in the back of the belly). It is for people whose tumor is removable and who have not had previous radiation in the same area.
This trial tests a new way of giving radiation called proton spatially fractionated radiotherapy (P-SFRT) combined with standard radiation for people with a type of sarcoma in the back of the belly. The goal is to see if this combination can treat the tumor more effectively.
This trial tests a new way of giving radiation therapy (called spatially fractionated radiotherapy) combined with a treatment strategy called PraG (pembrolizumab and granulocyte-macrophage colony-stimulating factor) for people with soft tissue sarcoma that cannot be removed or has spread. The goal is to see if the combination can help shrink or control the cancer.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
Hear when a new Retroperitoneal Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.